LifeMD Forms Exclusive Telehealth Partnership for XYOSTED Testosterone Program
LFMD sits 91% above its 52-week low of $2.56.
Summary
LifeMD announced an exclusive co-marketing and pharmacy partnership with Halozyme's Antares Pharma for a direct-to-patient XYOSTED testosterone program, launching in July 2026.
Key Events · M&A and Partnerships · LFMD
-
Exclusive Co-Marketing Partnership
LifeMD will serve as the exclusive telehealth co-marketing partner for XYOSTED, an FDA-approved once-weekly subcutaneous testosterone auto-injector, through a direct-to-patient self-pay program.
-
Integrated Care and Pharmacy Services
LifeMD's affiliated medical group will evaluate patients, and its pharmacy will be the preferred dispensing pharmacy for the program, shipping XYOSTED directly to patients.
-
Joint Investment in Market Expansion
LifeMD and Antares Pharma will collaborate on, and jointly invest in, consumer education and promotional initiatives to expand awareness of testosterone deficiency and the program.
-
Transparent Pricing and Market Opportunity
The program offers an all-inclusive price of approximately $249 per month, covering both medication and care, targeting millions of men with hypogonadism.
Analysis · LFMD · Industrial Applications And Services
This collaboration positions LifeMD as the exclusive telehealth co-marketing and preferred pharmacy partner for XYOSTED, an FDA-approved testosterone auto-injector. The program, launching in July 2026, targets a large market of men with hypogonadism by offering a transparent, all-inclusive monthly price for medication and care. This strategic move leverages LifeMD's virtual care platform and pharmacy infrastructure, potentially providing a significant new revenue stream and addressing financial stability concerns highlighted by a recent debt covenant breach.
At the time of this filing, LFMD was trading at $4.88 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $229.7M. The 52-week trading range was $2.56 to $15.84. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.